Soligenix Inc. NASDAQ: SNGX, a late-stage biopharmaceutical company, experienced an astonishing surge Tuesday. At the time of writing, the stock had soared nearly 400%. This dramatic increase, accompanied by a substantial rise in trading volume, warrants a closer look at the catalyst behind this movement and the company's fundamentals. This surge comes amidst increasing interest in small-cap stocks, which have seen a resurgence lately. Summer trading favors volatile market moves in low float names and has d ...

Shares of Soligenix (NASDAQ:SNGX) are surging higher by over 300% following an update on the biopharmaceutical company's study of its HyBryte treatment. HyBryte focuses on patients with early-stage cutaneous T-cell lymphoma (CTCL). According to the press release: "Patients have responded positively to HyBryte™ therapy with 75% (3 of the 4 subjects who have completed at least 12 weeks of therapy) already achieving "Treatment Success", as predefined in the study's protocol as ≥50% improvement in their cumulat ...

Loading... U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Tuesday. Check This Out: Nvidia To Rally Over 40%? Here Are 10 Top Analyst Forecasts For Tuesday Information technology shares jumped by 0.8% on Tuesday. Top Headline Equities Trading UP Equities Trading DOWN Also Check This Out: How To Earn $500 A Month From PepsiCo Stock Ahead Of Q2 Earnings In commodity news, oil traded down 1% to $81.53 while gold traded up 0.1% at $2,366.50. Euro zone As ...

Core Insights - HyBryte therapy has shown positive responses in patients, with three out of four subjects achieving "Treatment Success" after at least 12 weeks of treatment [2][9] - The Phase 3 FLASH study demonstrated the efficacy and promising safety profile of HyBryte, addressing the limited treatment options for early-stage cutaneous T-cell lymphoma (CTCL) patients [4][10] - The interim update from Soligenix indicates ongoing collaboration with the FDA for further studies, including a confirmatory Phase 3 placebo-controlled study [6] Study Details - The open-label study (protocol HPN-CTCL-04) enrolled ten patients, with six patients treated for up to 44 weeks [3][13] - Initial results from the expanded use of HyBryte in a real-world setting were described as "promising," supporting previous positive Phase 2 and 3 clinical trial results [10] - Two of the three patients who achieved Treatment Success did so within the first 12 weeks, while the third achieved success at 18 weeks [9] Efficacy and Safety - The study revealed that 60% of patients treated with HyBryte achieved a 50% or better improvement in their mCAILS score, compared to 20% of patients treated with Valchlor [11] - HyBryte has been reported to have a favorable safety profile, with no treatment-related adverse events observed in all patients [14] Market Reaction - Following the positive news, Soligenix Inc (SNGX) shares surged by 221.5%, reaching $6.43, with a trading volume of 23.6 million shares [7][8]

Group 1 - Soligenix (NASDAQ:SNGX) stock has surged by 296% following positive data from its late-stage HyBryte treatment for early-stage cutaneous T-cell lymphoma (CTCL) [4][5] - In a 12-month study, six patients were enrolled, with four patients achieving a 50% improvement in their cumulative mCAILS score compared to baseline after at least 12 weeks of treatment [1][6] - Heavy trading activity was noted, with over 46 million SNGX shares changing hands, significantly above the daily average of approximately 222,000 shares [2] Group 2 - The company anticipates improved outcomes for patients with continued treatment and plans to embark on a confirmatory Phase 3 replication study later this year [5] - The interim data indicates that one patient has shown significant improvement over 18 weeks, contributing to the overall positive outlook for the therapy [1][6]

Study Supported by $2.6 Million FDA Orphan Products Development Grant "We are pleased with the initial study results and with the FDA's support of the IIS that provides CTCL patients an opportunity to access HyBryte™ in an open-label setting," stated Christopher J. Schaber, President and CEO of Soligenix, Inc. "CTCL is an incredibly difficult to treat orphan disease and remains an area of unmet medical need with a very limited number of safe and effective treatment options. Following the initial Phase 3 FLA ...

"Following the positive results from the previous Phase 2 and 3 studies where I previously participated in evaluating HyBryte™, we were excited to support Soligenix's effort to conduct a prospective comparative assessment of HyBryte™ versus Valchlor®," stated Dr. Brian Poligone, Director of the Rochester Skin Lymphoma Medical Group and Principal Investigator for the comparability study. "Despite the small study sample size and a randomization that lead to the HyBryte™ group having patients with more extensi ...

Advanced subunit vaccine technology, including SuVax™ and MarVax™, to be discussed alongside mRNA and viral vectored vaccine approaches Oral Presentation / Panel Discussion: Under the Company's Public Health Solutions business segment, Soligenix is developing thermostabilized subunit vaccines. Thermostabilization is achieved by using a combination of Generally Recognized as Safe (GRAS) excipients and lyophilization (freeze-drying) to yield a single-vial presentation of vaccine that is stable at ambient and ...

In addition to the positive clinical results to date, Soligenix has received regulatory validation with the granting of Orphan Drug Designation and Fast Track Status by the U.S. Food and Drug Administration (FDA), and Orphan Designation by the European Medicines Agency (EMA) for HyBryte™ in the treatment of early-stage CTCL. The full article can be found at: https://prismmarketview.com/prism-marketview-highlights-soligenixs- promising-hybryte-replication-trial-setting-the-stage-for-success/ NEW YORK, June 0 ...

Common Stock Will Begin Trading on Split-Adjusted Basis on June 6, 2024 PRINCETON, N.J., May 31, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 16 pre-split shares. The reverse stock split will become ...